BlackRock Advisors’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-142,544
| Closed | -$1.28M | – | 3831 |
|
|
2016
Q3 | $1.28M | Sell |
142,544
-129,350
| -48% | -$920K | ﹤0.01% | 1687 |
|
|
2016
Q2 | $1.46M | Buy |
271,894
+1,698
| +0.6% | +$8.71K | ﹤0.01% | 1591 |
|
|
2016
Q1 | $1.24M | Sell |
270,196
-18,562
| -6% | -$74.6K | ﹤0.01% | 1635 |
|
|
2015
Q4 | $1.5M | Sell |
288,758
-17,504
| -6% | -$102K | ﹤0.01% | 1524 |
|
|
2015
Q3 | $1.85M | Buy |
306,262
+81,032
| +36% | +$993K | ﹤0.01% | 1390 |
|
|
2015
Q2 | $3.56M | Buy |
225,230
+143,800
| +177% | +$1.75M | ﹤0.01% | 1085 |
|
|
2015
Q1 | $885K | Buy |
81,430
+46,027
| +130% | +$470K | ﹤0.01% | 1641 |
|
|
2014
Q4 | $372K | Sell |
35,403
-1,419
| -4% | -$13.9K | ﹤0.01% | 2216 |
|
|
2014
Q3 | $353K | Sell |
36,822
-2,873
| -7% | -$29.3K | ﹤0.01% | 2240 |
|
|
2014
Q2 | $458K | Sell |
39,695
-4,707
| -11% | -$42.9K | ﹤0.01% | 2074 |
|
|
2014
Q1 | $444K | Buy |
44,402
+4,591
| +12% | +$66.3K | ﹤0.01% | 2136 |
|
|
2013
Q4 | $518K | Buy |
39,811
+3,260
| +9% | +$44.9K | ﹤0.01% | 2015 |
|
|
2013
Q3 | $545K | Buy |
36,551
+2,461
| +7% | +$29.5K | ﹤0.01% | 1836 |
|
|
2013
Q2 | $319K | Buy |
+34,090
| New | +$231K | ﹤0.01% | 2160 |
|
BlackRock Advisors's RPTP Position: Q4 2016 in Review
BlackRock Advisors sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 142,544 shares — an estimated $1.28M sold.
BlackRock Advisors first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $3.56M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- BlackRock Advisors reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- BlackRock Advisors sold 142,544 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $1.28M.
- BlackRock Advisors first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- BlackRock Advisors's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $3.56M in Q2 2015.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.